Drug Profile
Research programme: immunological disorders therapeutics - Evotec SE/UCB
Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Evotec AG; UCB
- Developer Evotec SE; UCB
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders; Inflammation
Most Recent Events
- 07 Dec 2022 Early research is still ongoing for Immunological disorders and Inflammation in Germany
- 28 Mar 2022 No recent reports of development identified for research development in Immunological-disorders in Germany
- 18 Mar 2020 The research programme is still in early research for the treatment of Immunological disorders in Germany (Evotec pipeline, March 2020)